Advertisement
Mayo Clinic Proceedings Home

Adult Acute Myeloid Leukemia

  • Elias J. Jabbour
    Affiliations
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston
    Search for articles by this author
  • Elihu Estey
    Affiliations
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston
    Search for articles by this author
  • Hagop M. Kantarjian
    Correspondence
    Address correspondence to Hagop M. Kantarjian, MD, Department of Leukemia, Box 428, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com
    Affiliations
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston
    Search for articles by this author
      Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging. Standard regimens using cytarabine and anthracyclines for induction followed by some form of postremission therapy produce response rates of 60% to 70%, with less than 20% of all patients achieving long-term disease-free survival. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Such targeted therapies offer the promise of better antileukemic activity in adult AML.
      AHD (antecedent hematologic disorder), ALSG (Australian Leukemia Study Group), AML (acute myeloid leukemia), APL (acute promyelocytic leukemia), As2O3 (arsenic trioxide), ATRA (all-trans retinoic acid), CALGB (Cancer and Leukemia Group B), CR (complete remission), CRD1 (duration of first remission), DIC (disseminated intravascular coagulation), ECOG (Eastern Cooperative Oncology Group), FAB (French-American-British), MRC (Medical Research Council), PCR (polymerase chain reaction), RFS (relapse-free survival), SWOG (Southwest Oncology Group), WBC (white blood cell), WHO (World Health Organization)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • O'Donnell MR
        Acute leukemias.
        in: Pazdur R Coia LR Hoskins WJ Wagman LD Cancer Management: A Multidisciplinary Approach. 8th ed. CMP Healthcare Media, Oncology Publishing Group, Manhasset, NY2004: 747-772
        • Foon KA
        • Casciato DA
        Acute leukemia.
        in: Casciato DA Lowitz BB Manual of Clinical Oncology. 3rd ed. Little, Brown and Co, New York, NY1995: 431-445
        • Abraham J
        • Monahan BP
        The acute leukemias.
        in: Abraham J Allegra CJ Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, Philadelphia, Pa2001: 271-285
        • Douer D
        • Preston-Martin S
        • Chang E
        • Nichols PW
        • Watkins KJ
        • Levine AM
        High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.
        Blood. 1996; 87: 308-313
        • Estey E
        • Thall P
        • Kantarjian H
        • Pierce S
        • Kornblau S
        • Keating M
        Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia.
        Leukemia. 1997; 11: 1661-1664
        • Pedersen-Bjergaard J
        • Christiansen DH
        • Andersen MK
        • Skovby F
        Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities.
        Leukemia. 2002; 16: 2177-2184
        • Dong F
        • Brynes RK
        • Tidow N
        • Welte K
        • Lowenberg B
        • Touw IP
        Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.
        N Engl J Med. 1995; 333: 487-493
        • West RR
        • Stafford DA
        • White AD
        • Bowen DT
        • Padua RA
        Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure.
        Blood. 2000; 95: 2093-2097
        • Crane MM
        • Strom SS
        • Halabi S
        • et al.
        Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia.
        Cancer Epidemiol Biomarkers Prev. 1996; 5: 639-644
        • Ayton PM
        • Cleary ML
        Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
        Genes Dev. 2003; 17: 2298-2307
        • Armstrong SA
        • Staunton JE
        • Silverman LB
        • et al.
        MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.
        Nat Genet. 2002; 30: 41-47
        • Haferlach T
        • Schoch C
        • Loffler H
        • et al.
        Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
        J Clin Oncol. 2003; 21: 256-265
        • Appelbaum FR
        Acute myeloid leukemia in adults.
        in: Abeloff MD Armitage JO Niederhuber JE Kastan M McKenna WG Clinical Oncology. 3rd ed. Elsevier, Philadelphia, Pa2004: 2825-2848
        • Jabbour E
        • Ribrag V
        Acute tumor lysis syndrome: update on therapy [in French].
        Rev Med Interne. 2005; 26: 27-32
        • Novotny JR
        • Muller-Beissenhirtz H
        • Herget-Rosenthal S
        • Kribben A
        • Duhrsen U
        Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome.
        Eur J Haematol. 2005; 74: 501-510
        • Tan D
        • Hwang W
        • Goh YT
        Therapeutic leukapheresis in hyperleukocytic leukaemias—the experience of a tertiary institution in Singapore.
        Ann Acad Med Singapore. 2005; 34: 229-234
        • Bennett JM
        • Catovsky D
        • Daniel MT
        • French-American-British (FAB) Co-operative Group
        • et al.
        Proposals for the classification of the acute leukaemias.
        Br J Haematol. 1976; 33: 451-458
        • Vardiman JW
        • Harris NL
        • Brunning RD
        The World Health Organization (WHO) classification of the myeloid neoplasms.
        Blood. 2002; 100: 2292-2302
        • Klobusicka M
        • Kusenda J
        • Babusikova O
        Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
        Neoplasma. 2005; 52: 211-218
        • Wang XB
        • Zheng JE
        • Gu JX
        • et al.
        Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia [in Chinese].
        Ai Zheng. 2005; 24: 667-671
        • Roumier C
        • Eclache V
        • Imbert M
        • et al.
        M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH).
        Blood. 2003; 101: 1277-1283
        • Tallman MS
        • Neuberg D
        • Bennett JM
        • et al.
        Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
        Blood. 2000; 96: 2405-2411
        • Bennett JM
        • Catovsky D
        • Daniel MT
        • et al.
        Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group.
        Ann Intern Med. 1985; 103: 620-625
        • Freireich EJ
        • Gehan EA
        • Sulman D
        • Boggs DR
        • Frei III, E
        The effect of chemotherapy on acute leukemia in the human.
        J Chronic Dis. 1961; 14: 593-608
        • Cheson BD
        • Bennett JM
        • Kopecky KJ
        • et al.
        Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22:576].
        J Clin Oncol. 2003; 21: 4642-4649
        • de Lima M
        • Strom SS
        • Keating M
        • et al.
        Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
        Blood. 1997; 90: 4719-4724
        • Lopez G
        • Giles F
        • Cortes J
        • et al.
        Sub-types of resistant disease in patients with AML, RAEB-t, or RAEB who fail initial induction chemotherapy [abstract].
        Blood. 2001; 98 (Abstract 1388.): 329a
        • Giles FJ
        • Shen Y
        • Kantarjian HM
        • et al.
        Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival.
        Leuk Lymphoma. 2001; 42: 67-73
        • Seymour JF
        • Pierce SA
        • Kantarjian HM
        • Keating MJ
        • Estey EH
        Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
        Leukemia. 1994; 8: 823-826
        • Rowe JM
        • Kim HT
        • Cassileth PA
        • Litzow MR
        • Wiernik PH
        • Tallman MS
        Time to complete remission is not a significant prognostic factor in AML: a report on 1,959 consecutive patients registered to 6 studies of the Eastern Cooperative Oncology Group (ECOG) [abstract].
        Blood. 2004; 104 (Abstract 862.): 246a
        • Preisler HD
        • Anderson K
        • Rai K
        • et al.
        The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years.
        Br J Haematol. 1989; 71: 189-194
        • Elonen E
        • Almqvist A
        • Hanninen A
        • et al.
        Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
        Leukemia. 1998; 12: 1041-1048
        • Büchner T
        • Hiddemann W
        • Wörmann B
        • German AMLCG
        Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?.
        Intl J Hematol. 2000; 72: 285-289
        • Büchner T
        • Urbanitz D
        • Hiddemann W
        • et al.
        Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
        J Clin Oncol. 1985; 3: 1583-1589
        • Büchner T
        • Hiddemann W
        • Berdel WE
        • et al.
        Requestioning the role of prolonged maintenance chemotherapy in AML: a randomized trial by the German AML Cooperative Group Updated [abstract].
        Blood. 2001; 98 (Abstract 1933.): 462a
        • Rees JK
        • Gray RG
        • Wheatley K
        • MRC Leukaemia in Adults Working Party
        Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost: principal report of the Medical Research Council's AML9 study.
        Br J Haematol. 1996; 94: 89-98
        • Sauter C
        • Berchtold W
        • Fopp M
        • et al.
        Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival.
        Lancet. 1984; 1: 379-382
        • Estey EH
        Therapeutic options for acute myelogenous leukemia.
        Cancer. 2001; 92: 1059-1073
        • Estey E
        • Keating MJ
        • McCredie KB
        • Bodey GP
        • Freireich EJ
        Causes of initial remission induction failure in acute myelogenous leukemia.
        Blood. 1982; 60: 309-315
        • Estey E
        • Smith TL
        • Keating MJ
        • McCredie KB
        • Gehan EA
        • Freireich EJ
        Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.
        Leukemia. 1989; 3: 257-263
        • Sekeres MA
        • Peterson B
        • Dodge RK
        • Cancer and Leukemia Group B
        • et al.
        Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
        Blood. 2004; 103: 4036-4042
        • Grimwade D
        • Walker H
        • Oliver F
        • Medical Research Council Adult and Children's Leukaemia Working Parties
        • et al.
        The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.
        Blood. 1998; 92: 2322-2333
        • Estey E
        • Thall P
        • Beran M
        • Kantarjian H
        • Pierce S
        • Keating M
        Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
        Blood. 1997; 90: 2969-2977
        • Kiyoi H
        • Naoe T
        • Nakano Y
        • et al.
        Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
        Blood. 1999; 93: 3074-3080
        • Kottaridis PD
        • Gale RE
        • Frew ME
        • et al.
        The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
        Blood. 2001; 98: 1752-1759
        • Leith CP
        • Kopecky KJ
        • Godwin J
        • et al.
        Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study.
        Blood. 1997; 89: 3323-3329
        • Leith CP
        • Kopecky KJ
        • Chen IM
        • et al.
        Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glyco-protein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study.
        Blood. 1999; 94: 1086-1099
        • Baldus CD
        • Tanner SM
        • Ruppert AS
        • et al.
        BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study.
        Blood. 2003; 102: 1613-1618
        • Huyghe P
        • Coiteux V
        • Sagot C
        • et al.
        Mutations of CEBPA, FLT3 and RAS in patients with de novo adult leukemia: a study from the Acute Leukemia French Association (ALFA) [abstract].
        Blood. 2003; 102 (Abstract 336.): 99a
        • Schnittger S
        • Thiede C
        • Kern W
        • et al.
        Partial tandem duplication of the MLL-gene (MLL-PTD): a metaanlysis of 2885 AML patients enrolled into the German AMLCG99 and AML96 SHG trials [abstract].
        Blood. 2003; 102 (Abstract 340.): 100a
        • Frohling S
        • Schlenk RF
        • Kreitmeier S
        • et al.
        CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations [abstract].
        Blood. 2003; 102 (Abstract 337.): 99a
        • Falini B
        • Mecucci C
        • Tiacci E
        • GIMEMA Acute Leukemia Working Party
        • et al.
        Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype [published correction appears in N Engl J Med. 2005;352:740].
        N Engl J Med. 2005; 352: 254-266
        • Berman E
        • Heller G
        • Santorsa J
        • et al.
        Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
        Blood. 1991; 77: 1666-1674
        • Wiernik PH
        • Banks PL
        • Case Jr, DC
        • et al.
        Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
        Blood. 1992; 79: 313-319
        • Vogler WR
        • Velez-Garcia E
        • Weiner RS
        • et al.
        A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study.
        J Clin Oncol. 1992; 10: 1103-1111
        • Wheatley K
        • AML Collaborative Group L
        Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML) [abstract].
        Blood. 1995; 86 (Abstract 1724.): 434a
        • Rowe JM
        • Neuberg D
        • Friedenberg W
        • et al.
        A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastren Cooperative Oncology Group (E3993) [abstract].
        Blood. 1998; 92 (Abstract 1284.): 313a
        • Vignetti M
        • De Witte TM
        • Suciu S
        • et al.
        Daunorubicin (DNR) vs mitoxantrone (MTZ) vs idarubicin administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem cell transplantation (SCT): results of the EORTC-GIMEMA [abstract].
        Blood. 2003; 102 (Abstract 611.): 175a
        • Bishop JF
        • Lowenthal RM
        • Joshua D
        • Australian Leukemia Study Group
        • et al.
        Etoposide in acute nonlymphocytic leukemia.
        Blood. 1990; 75: 27-32
        • Russo D
        • Malagola M
        • Martinelli G
        • et al.
        Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years [abstract].
        Blood. 2004; 104 (Abstract 878.): 250a
        • Mayer RJ
        • Davis RB
        • Schiffer CA
        • Cancer and Leukemia Group B
        • et al.
        Intensive postremission chemotherapy in adults with acute myeloid leukemia.
        N Engl J Med. 1994; 331: 896-903
        • Cassileth PA
        • Lynch E
        • Hines JD
        • et al.
        Varying intensity of post-remission therapy in acute myeloid leukemia.
        Blood. 1992; 79: 1924-1930
        • Weick JK
        • Kopecky KJ
        • Appelbaum FR
        • et al.
        A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
        Blood. 1996; 88: 2841-2851
        • Bishop JF
        • Matthews JP
        • Young GA
        • Bradstock K
        • Lowenthal RM
        Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
        Leuk Lymphoma. 1998; 28: 315-327
        • Neubauer A
        • Maharry K
        • Marcucci G
        • et al.
        Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: a Cancer and Leukemia Group B (CALGB) study [abstract].
        J Clin Oncol. 2005; 23 (Abstract 6514.): 563s
        • Kern W
        • Estey EH
        High-dose cytosine arabinoside in induction treatment of acute myeloid leukemia: meta-analysis of three trials involving 1691 randomized patients [abstract].
        Blood. 2002; 100 (Abstract 581.): 155a
        • Estey EH
        How I treat older patients with AML.
        Blood. 2000; 96: 1670-1673
      1. Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromes. Cancer, In press.

        • Zittoun RA
        • Mandelli F
        • Willemze R
        • European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups
        • et al.
        Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia.
        N Engl J Med. 1995; 332: 217-223
        • Cassileth PA
        • Harrington DP
        • Appelbaum FR
        • et al.
        Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
        N Engl J Med. 1998; 339: 1649-1656
        • Burnett AK
        • Goldstone AH
        • Stevens RM
        • UK Medical Research Council Adult and Children's Leukaemia Working Parties
        • et al.
        Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial.
        Lancet. 1998; 351: 700-708
        • Burnett AK
        • Goldstone AH
        • Stevens RM
        • et al.
        Biologic characteristics of disease determines the outcome of allogeneic or autologous BMT in CR1 [abstract].
        Blood. 1995; 86 (Abstract 2452.): 616a
        • Burnett AK
        Transplantation in first remission of acute myeloid leukemia [editorial].
        N Engl J Med. 1998; 339: 1698-1700
        • Reiffers J
        • Stoppa AM
        • Rigal-Huguet F
        • BGMT Group
        • et al.
        Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies).
        Bone Marrow Transplant. 1991; 7: 36
        • Schiller GJ
        • Nimer SD
        • Territo MC
        • Ho WG
        • Champlin RE
        • Gajewski JL
        Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
        J Clin Oncol. 1992; 10: 41-46
        • Archimbaud E
        • Thomas X
        • Michallet M
        • et al.
        Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia.
        J Clin Oncol. 1994; 12: 262-267
        • Hewlett J
        • Kopecky KJ
        • Head D
        • et al.
        A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study.
        Leukemia. 1995; 9: 562-569
        • Woods WG
        • Neudorf S
        • Gold S
        • et al.
        A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
        Blood. 2001; 97: 56-62
        • Slavin S
        • Nagler A
        • Shapira MY
        • Aker M
        • Gabriel C
        • Or R
        Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.
        J Clin Immunol. 2002; 22: 64-69
        • Tallman MS
        • Rowlings PA
        • Milone G
        • et al.
        Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.
        Blood. 2000; 96: 1254-1258
        • Giralt S
        • Estey E
        • Albitar M
        • et al.
        Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
        Blood. 1997; 89: 4531-4536
        • Slavin S
        • Nagler A
        • Naparstek E
        • et al.
        Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
        Blood. 1998; 91: 756-763
        • McSweeney PA
        • Niederwieser D
        • Shizuru JA
        • et al.
        Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
        Blood. 2001; 97: 3390-3400
        • Ringden O
        • Labopin M
        • Bacigalupo A
        • et al.
        Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.
        J Clin Oncol. 2002; 20: 4655-4664
        • Andersson BS
        • Kashyap A
        • Couriel D
        • et al.
        Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit [letter].
        Biol Blood Marrow Transplant. 2003; 9: 722-724
        • Godwin JE
        • Kopecky KJ
        • Head DR
        • et al.
        A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031).
        Blood. 1998; 91: 3607-3615
        • Heil G
        • Hoelzer D
        • Sanz MA
        • International Acute Myeloid Leukemia Study Group
        • et al.
        A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia.
        Blood. 1997; 90: 4710-4718
        • Moore JO
        • Dodge RK
        • Amrein PC
        • et al.
        Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
        Blood. 1997; 89: 780-788
        • Stone RM
        • O'Donnell MR
        • Sekeres MA
        Acute myeloid leukemia.
        Hematology. January 2004; : 98-117
        • Trial to Reduce Alloimmunization to Platelets Study Group
        Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
        N Engl J Med. 1997; 337: 1861-1870
        • Mattiuzzi G
        • Alvarado G
        • Alvarez R
        • et al.
        Causes of death in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC) [abstract].
        Blood. 2003; 102 (Abstract 3267.): 878a
        • Rex JH
        • Anaissie EJ
        • Boutati E
        • Estey E
        • Kantarjian H
        Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
        Leukemia. 2002; 16: 1197-1199
        • Jeha S
        Tumor lysis syndrome.
        Semin Hematol. 2001; 38: 4-8
        • Mattiuzzi G
        • Pierce S
        • Faderl S
        • et al.
        Causes of pneumonia (PN) in patients (PTS) with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC) [abstract].
        Blood. 2000; 96 (Abstract 1399.): 324a
        • Estey EH
        Treatment of relapsed and refractory acute myelogenous leukemia.
        Leukemia. 2000; 14: 476-479
        • Estey E
        • Kornblau S
        • Pierce S
        • Kantarjian H
        • Beran M
        • Keating M
        A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter].
        Blood. 1996; 88: 756
        • Buckner CD
        • Sanders J
        • Appelbaum FR
        Allogeneic marrow transplantation for acute non-lymphoblastic leukemia: first remission versus after first relapse.
        Bone Marrow Transplant. 1989; 4: 244-246
        • Forman SJ
        • Schmidt GM
        • Nademanee AP
        • et al.
        Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.
        J Clin Oncol. 1991; 9: 1570-1574
        • Biggs JC
        • Horowitz MM
        • Gale RP
        • et al.
        Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy.
        Blood. 1992; 80: 1090-1093
        • Sievers EL
        • Larson LA
        • Stadtmauer EA
        • Mylotarg Study Group
        • et al.
        Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
        J Clin Oncol. 2001; 19: 3244-3254
        • De Angelo DJ
        • Stone RM
        • Durrant S
        • et al.
        Gentuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials [abstract].
        Blood. 2003; 102 (Abstract 341.): 100a
        • Giles F
        • Estey E
        • O'Brien S
        Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
        Cancer. 2003; 98: 2095-2104
        • Stone RM
        • Klimek V
        • DeAngelo DJ
        • et al.
        PKC412, an oral FLT 3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial [abstract].
        Blood. 2002; 100 (Abstract 316.): 86a
        • Smith D
        • Levis M
        • Brown P
        • et al.
        Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia [abstract].
        Blood. 2002; 100 (Abstract 314.): 85a
        • Karp JE
        • Lancet JE
        • Kaufmann SH
        • et al.
        Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
        Blood. 2001; 97: 3361-3369
        • Lancet JE
        • Karp JE
        • Gotlib J
        • et al.
        Zarnestra™ (R115777) in previously untreated poor-risk AML and MDS: preliminary results of a phase II trial [abstract].
        Blood. 2002; 100 (Abstract 2200.): 560a
        • Marcucci G
        • Stock W
        • Kliovit MI
        • et al.
        In vivo activity of Genasense™ (G3139) (GS), a bcl-2 antisense oligonucleotide in previously untreated patients (pts) >60 years with acute myeloid leukemia (AML): initial report of phase I study in combination with daunorubicin and cytarabine [abstract].
        Blood. 2002; 100 (Abstract 1307.): 337a
        • Hussong JW
        • Rodgers GM
        • Shami PJ
        Evidence of increased angiogenesis in patients with acute myeloid leukemia.
        Blood. 2000; 95: 309-313
        • Cortes J
        • Kantarjian H
        • Albitar M
        • et al.
        A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
        Cancer. 2003; 97: 1234-1241
        • Ravandi F
        • Kantarjian H
        • Giles F
        • Cortes J
        New agents in acute myeloid leukemia and other myeloid disorders.
        Cancer. 2004; 100: 441-454
        • Baer MR
        • George SL
        • Dodge RK
        • et al.
        Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720.
        Blood. 2002; 100: 1224-1232
        • Kantarjian HM
        • O'Brien SM
        • Estey E
        • et al.
        Decitabine studies in chronic and acute myelogenous leukemia.
        Leukemia. 1997; 11: S35-S36
        • Kantarjian HM
        • Gandhi V
        • Kozuch P
        • et al.
        Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
        J Clin Oncol. 2003; 21: 1167-1173
        • Faderl S
        • Gandhi V
        • O'Brien S
        • et al.
        Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
        Blood. 2005; 105: 940-947
        • Giles FJ
        • Kantarjian HM
        • Cortes JE
        • et al.
        Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
        J Clin Oncol. 2003; 21: 1722-1727
        • Kantarjian HM
        • Gandhi V
        • Cortes J
        • et al.
        Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
        Blood. 2003; 102: 2379-2386
        • Burnett AK
        • Russell N
        • Kell JW
        • Milligan D
        • Culligan D
        A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy [abstract].
        Blood. 2004; 104 (Abstract 869.): 248a
        • Faderl S
        • Gandhi V
        • Verstovsek S
        • et al.
        Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [abstract].
        Blood. 2004; 104 (Abstract 875.): 250a
        • Giles FJ
        • Cortes JE
        • Baker SD
        • et al.
        Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
        J Clin Oncol. 2001; 19: 762-771
        • Giles FJ
        • Garcia-Manero G
        • Cortes JE
        • et al.
        Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
        J Clin Oncol. 2002; 20: 656-664
        • Giles FJ
        • Faderl S
        • Thomas DA
        • et al.
        Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias [published correction appears in J Clin Oncol. 2004;22:1351].
        J Clin Oncol. 2003; 21: 1050-1056
        • van der Holt B
        • Lowenberg B
        • Burnett AK
        • et al.
        The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
        Blood. 2005; 106: 2646-2654
        • Issa JP
        • Garcia-Manero G
        • Giles FJ
        • et al.
        Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies.
        Blood. 2004; 103: 1635-1640
        • Garcia-Manero
        • Kantarjian H
        • Sanchez-Gonzalez B
        • et al.
        Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia [abstract].
        Blood. 2004; 104 (Abstract 263.): 78a
        • Jabbour EJ
        • Yee KW
        • Giles FJ
        FLT-3 receptor tyrosine kinase as a drug target in leukemia.
        Futur Oncol. 2005; 1: 323-333
        • Melnick A
        • Licht JD
        Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.
        Blood. 1999; 93: 3167-3215
        • Lo Coco F
        • Diverio D
        • Falini B
        • Biondi A
        • Nervi C
        • Pelicci PG
        Genetic diagnosis and molecular monitoring in management of acute promyelocytic leukemia.
        Blood. 1999; 94: 12-22
        • Tallman MS
        • Kwaan HC
        Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
        Blood. 1992; 79: 543-553
        • Golomb HM
        • Rowley JD
        • Vardiman JW
        • Testa JR
        • Butler A
        “Microgranular” acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity.
        Blood. 1980; 55: 253-259
        • Dyck JA
        • Warrell Jr, RP
        • Evans RM
        • Miller Jr, WH
        Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-α protein.
        Blood. 1995; 86: 862-867
        • Avvisati G
        • Petti MC
        • Lo-Coco F
        • Gruppo Italiano Malattie Ematologische dell'Adulto Italian Cooperative Group
        • et al.
        Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
        Blood. 2002; 100: 3141-3146
        • Estey E
        • Thall PF
        • Pierce S
        • Kantargian H
        • Keating M
        Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
        J Clin Oncol. 1997; 15: 483-490
        • Fenaux P
        • Le Deley MC
        • Castaigne S
        • European APL 91 Group
        • et al.
        Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial.
        Blood. 1993; 82: 3241-3249
        • Fenaux P
        • Chastang C
        • Chomienne C
        • European APL Group
        • et al.
        Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: the European experience.
        Leuk Lymphoma. 1995; 16: 431-437
        • Tallman MS
        • Andersen JW
        • Schiffer CA
        • et al.
        All-trans retinoic acid acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
        Blood. 2002; 100: 4298-4302
        • Fenaux P
        • Chastang C
        • Chevret S
        • European APL Group
        • et al.
        A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.
        Blood. 1999; 94: 1192-1200
        • Tallman MS
        • Andersen JW
        • Schiffer CA
        • et al.
        Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.
        Blood. 2000; 95: 90-95
        • Jurcic JG
        • Nimer SD
        • Scheinberg DA
        • DeBlasio T
        • Warrell Jr, RP
        • Miller Jr, WH
        Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia.
        Blood. 2001; 98: 2651-2656
        • Diverio D
        • Rossi V
        • Avvisati G
        • et al.
        Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial.
        Blood. 1998; 92: 784-789
        • Sanz MA
        • Lo Coco F
        • Martin G
        • et al.
        Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
        Blood. 2000; 96: 1247-1253
        • Lo Coco F
        • Diverio D
        • Avvisati G
        • et al.
        Therapy of molecular relapse in acute promyelocytic leukemia.
        Blood. 1999; 94: 2225-2229
        • Shao W
        • Fanelli M
        • Ferrara FF
        • et al.
        Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells.
        J Natl Cancer Inst. 1998; 90: 124-133
        • Soignet SL
        • Frankel SR
        • Douer D
        • et al.
        United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
        J Clin Oncol. 2001; 19: 3852-3860
        • Dombret H
        • Rousselot P
        • Hermine O
        • et al.
        Treatment of relapsing acute promyelocytic leukemia with arsenic trioxide (As203) ± all-trans retinoic acid (ATRA): the French As98 study [abstract].
        Blood. 2000; 96 (Abstract 3578.): 828a
        • Niu C
        • Yan H
        • Yu T
        • et al.
        Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
        Blood. 1999; 94: 3315-3324
        • Estey E
        Therapeutic research in untreated acute promyelocytic leukemia.
        Leukemia. 2005; 19: 913-915
        • Shen ZX
        • Shi ZZ
        • Fang J
        • et al.
        All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
        Proc Natl Acad Sci U S A. 2004; 101: 5328-5335
        • George B
        • Mathews V
        • Vishwabandhya A
        • Srivastava A
        • Chandy M
        Arsenic trioxide (As2O3) in the treatment of patients with newly diagnosed acute promyelocytic leukemia (APML)—toxicity and outcome [abstract].
        Blood. 2004; 104 (Abstract 889.): 254a
        • Ghavamzadeh A
        • Alimoghaddam K
        • Ghaffari H
        • et al.
        Treatment of new cases of acute promyelocytic leukaemia by arsenic trioxide [abstract].
        Blood. 2004; 104 (Abstract 396.): 116a
        • Estey EH
        • Garcia-Manero G
        • Ferrajoli A
        • et al.
        Use of all-transretinoic acid (ATRA) + arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia (APL) [abstract].
        Blood. 2004; 104 (Abstract 393.): 115a
        • Lu DP
        • Qiu JY
        • Jiang B
        • et al.
        Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report.
        Blood. 2002; 99: 3136-3143
        • Au WY
        • Kumana CR
        • Kou M
        • et al.
        Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
        Blood. 2003; 102: 407-408
        • Jurcic J
        • DeBlasio T
        • Dumont L
        • Yao TJ
        • Scheinberg DA
        Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
        Clin Cancer Res. 2000; 6: 372-380
        • Estey EH
        • Giles F
        • Beran M
        • et al.
        Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia.
        Blood. 2002; 99: 4222-4224
        • Baudard M
        • Marie JP
        • Cadiou M
        • Viguie F
        • Zittoun R
        Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.
        Br J Haematol. 1994; 86: 82-91
        • Sebban C
        • Archimbaud E
        • Coiffier B
        • et al.
        Treatment of acute myeloid leukemia in elderly patients: a retrospective study.
        Cancer. 1998; 61: 227-231
        • Johnson PR
        • Ryder WD
        • Yin JA
        Validation of a model to predict survival in elderly patients with acute myeloid leukaemia.
        Br J Haematol. 1995; 90: 954-956
        • Johnson PR
        • Yin JA
        Prognostic factors in elderly patients with acute myeloid laukaemia.
        Leuk Lymphoma. 1994; 16: 51-56
      2. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome-Predictive prognostic models for outcome. Pediatrics, In press.

        • Burnett AK
        • Milligan D
        • Prentice AG
        • et al.
        Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial [abstract].
        Blood. 2004; 104 (Abstract 872.): 249a
        • Menzin J
        • Lang K
        • Earle CC
        • Kerney D
        • Mallick R
        The outcomes and costs of acute myeloid leukemia among the elderly.
        Arch Intern Med. 2002; 162: 1597-1603